Logo Sangui

pdf_downloadicon
Downloads as PDF-File
190306-news-EN.pdf
190214-news-EN.pdf
181115-news_EN.pdf
181002-news_EN.pdf
180725_news_EN.pdf
180703_news_EN.pdf
180522_news_EN.pdf
180504_news_EN.pdf
180214_news_EN.pdf
180119_news_EN.pdf
171121_news_EN.pdf
171110_news_EN.pdf
171023_news_EN.pdf
170712_news_EN.pdf
170224_Financials_EN.pdf
170112_Financials_EN.pdf
161221_Sales_EN.pdf
161122 financials_EN.pdf
161101 sales_agreements_EN.pdf
161014 news_EN.pdf
160929 news_EN.pdf
160606 news_EN.pdf
160201 preliminary figures_EN.pdf
151028 Preliminary 16Q1_EN.pdf
150929 Financials FY15_EN.pdf
150827 Financials FY15_EN.pdf
150626 Preliminary Prospectus.pdf
150602 EWMA_EN.pdf
150515 Financials 15Q3_EN.pdf
150512 Financing_EN.pdf
150318 Preclinical Results EN.pdf
150212 Financials 15Q2_EN.pdf
150203 Eastern Europe_EN.pdf
150128 ShareholderLetter_EN.pdf
150128 Preliminary Q2 Revenues_EN.pdf
141113 Financials 15Q1_EN.pdf
141111 Preclinical Results EN.pdf
141106 OTCQB EN.pdf
141103 Silanes EN.pdf
141007 Q1 Revenues_EN.pdf
140925 Financials FY14_EN.pdf
140806 ARDS_trials_EN2.pdf
140731 Wound Treatment Patent_EN.pdf
140729 Preliminary Q4 Revenues_EN.pdf
140526 woundspray_EN.pdf
140515 Financials 14Q3_EN.pdf
140425 start in vitro tests_EN.pdf
140214 Financials 14Q2_EN.pdf
140114 Shareholder Letter_en.pdf
131205 Three Partners_EN.pdf
131115 infirst_EN.pdf
131106 Financials 14Q1_EN.pdf
131015 ECCPS_EN.pdf
131008 Scherrer_EN.pdf
130927 Financials FY13_EN.pdf
130923 Colpharma EN.pdf
130917 FEA Award_EN.pdf
130910 Ramma_EN.pdf
130904 Hb Patent EN.pdf
130813 Wound Treatment Patent_EN.pdf
130716 MEDiLAB_EN.pdf
130521 PM 9M figures_E.pdf
130422 BiologiQ en.pdf
130409 Additiv_E.pdf
130322 Notiz Berlin_E.pdf
130215 Half year figures_E.pdf
130205 Prague study_published_E.pdf
121221 Mexiko Sales_E.pdf
121212 Prague study_E.pdf
121017 Pegylation patent granted E.pdf
120827 PM Complementing Agreement E.pdf
120813 PM 100 days E.pdf
news147_en.pdf
news146_en.pdf
news145_en.pdf
news144_en.pdf
news143_en.pdf
news142_en.pdf
news141_en.pdf
news140_en.pdf

Media Releases

Sangui BioTech:
Patent granted to Sangui for possible Septic Shock treatment

Witten, March, 06 2019:

The European Patent Office has granted a patent for Sangui's proposed technology/treatment (SBT 102) for septic shock patients, effective March, 6, 2019*. The patent follows up on animal studies carried out by the ECCPS (Excellence Cluster Cardio-Pulmonary System**), Giessen, Germany.

The studies conducted by the ECCPS have resulted in proof-of concept data, utilizing a related technology to Sangui's unique hemoglobin oxygen carrier technology which is already successfully employed by Granulox, a medical device for treatment of chronic wounds. Granulox is distributed by Sastomed GmbH, a fully owned subsidiary of Mölnlycke Health Care GmbH.

The co-authors of the ECCPS studies, Prof. Dr. Ralph Schermuly and Prof. Dr. Ardeshir Ghofrani, come to the conclusion: “We conclude that the intraperitoneal application of SBT 102 is an innovative and effective therapy to avoid tissue hypoxemia. The restoration of intestinal oxygenation will have impact on tissue integrity and finally patient survival.”

* Subject to Opposition Period of 9 Months (Article 99 EPC).
** The ECCPS (www.eccps.de) is a joint centre of the Justus-Liebig-University Giessen, the Goethe University Frankfurt and the Max-Planck-Institute for Heart and Lung Research in Bad Nauheim in the field of heart and lung research.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (2302) 915191
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions.  Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


Sangui BioTech:
- Sales of USD 55,367  in the first half-year
- Strong year-end-business

Witten, February, 14 2019:

In the first six months of fiscal year 2019 (to 30/06/2019) Sangui BioTech International Inc. achieved revenues from royalty income of USD 55,367. In the same period of the previous year the comparable revenue amounted to USD 55,082. Due to only slightly higher revenues of the wound spray Granulox, the resulting royalty income in the first half of the year remained at the level of the same period of the previous year.

While the first quarter lagged behind the previous year, royalty income in the second quarter clearly exceeded those of the prior-year period. For example, the strong year-end business in 2018 led to a rise in second-quarter royalty income revenues of USD 5,646 or 15% compared to the previous year.

As operating expenses increased USD 44,740 or 27% to USD 208,903 during the period, first half years operating loss increased USD 44,510 to USD 153,635 from the prior year. The operating loss for the second quarter of 2019, on the other hand, increased disproportionately by USD 8,801 compared to the previous year to USD 60,137.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (2302) 915191
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions.  Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


Sangui BioTech:
- Sales of USD 11,272 in the first quarter
- Mölnlycke takes over distribution of Granulox

Witten, November, 15, 2018:

In the first three months of fiscal year 2019 (to 30/06/2019) Sangui BioTech International Inc. achieved revenues from royalty income of USD 11,272. In the same period of the previous year the comparable revenue amounted to USD 16,636. Due to decreased revenues of the wound spray Granulox, the resulting royalty income in the first three months decreased by 32% compared to the same period of the previous year.

Operating expenses increased USD 30,276 or 41% to USD 104,697 during the period. This was mainly due to higher costs for consulting and general administration. The operating loss for the first three months increased by USD 35,709 to USD 93,498 compared to the same period last year.

On July 2, 2018, Mölnlycke Health Care GmbH acquired all shares of SastoMed GmbH. The associated scheduled restructuring was mainly responsible for the decline in Granulox's sales in the quarter under review. Over the coming months, the Mölnlycke Group has given priority to increasing the sales volume of Granulox.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (2302) 915191
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions.  Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.